PMID- 30223693
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20191210
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 19
IP  - 16
DP  - 2018 Nov
TI  - Ertugliflozin as a monotherapy for the treatment of type 2 diabetes.
PG  - 1841-1847
LID - 10.1080/14656566.2018.1525360 [doi]
AB  - Sodium-dependent glucose transporter 2 (SGLT2) inhibitors are novel, potent oral 
      anti-diabetic agents in a beta-cell function-independent manner, inhibiting 
      SGLT2-mediated renal glucose reabsorption and thus increasing urinary glucose 
      excretion. Ertugliflozin (Steglatro(TM)) is a new oral SGLT2 inhibitor for the 
      treatment of patients with type 2 diabetes mellitus (T2DM) as a monotherapy or in 
      combination with other anti-diabetic agents. Areas covered: This review 
      summarizes the collected data concerning the pharmacokinetics, clinical efficacy, 
      as well as safety and tolerability profiles of ertugliflozin given as a 
      monotherapy for the management of T2DM. Expert opinion: Good glycemic control is 
      crucial to the management of T2DM, and accordingly, anti-diabetic agents with 
      various anti-hyperglycemic mechanisms are developed one after another. Based on 
      the available clinical trials of ertugliflozin as a monotherapy for T2DM, it 
      could be found that ertugliflozin effectively improves the glycemic control, body 
      weight and blood pressure of patients with a low risk of hypoglycemia. It is also 
      found that ertugliflozin moderately reduces their blood pressure, which is 
      beneficial for decreasing the risk of cardiovascular disease. These attributes 
      show the good potential of ertugliflozin as an adjunct treatment to diet and 
      exercise for improving glycemic control in patients with T2DM.
FAU - Hu, Jingbo
AU  - Hu J
AD  - a Institute of Drug Discovery Technology , Ningbo University , Ningbo , China.
FAU - Deng, Aiping
AU  - Deng A
AD  - b Department of Pharmacy, The Central Hospital of Wuhan, Tongji Medical College , 
      Huazhong University of Science and Technology , Wuhan , China.
FAU - Zhao, Yufen
AU  - Zhao Y
AD  - a Institute of Drug Discovery Technology , Ningbo University , Ningbo , China.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Review
DEP - 20180924
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Bridged Bicyclo Compounds, Heterocyclic)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 6C282481IP (ertugliflozin)
SB  - IM
MH  - Bridged Bicyclo Compounds, 
      Heterocyclic/pharmacokinetics/pharmacology/*therapeutic use
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Double-Blind Method
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Sodium-Glucose Transporter 2 Inhibitors/pharmacology/*therapeutic use
OTO - NOTNLM
OT  - Ertugliflozin
OT  - SGLT2 inhibitor
OT  - monotherapy
OT  - type 2 diabetes mellitus
EDAT- 2018/09/19 06:00
MHDA- 2018/12/12 06:00
CRDT- 2018/09/19 06:00
PHST- 2018/09/19 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/09/19 06:00 [entrez]
AID - 10.1080/14656566.2018.1525360 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2018 Nov;19(16):1841-1847. doi: 
      10.1080/14656566.2018.1525360. Epub 2018 Sep 24.